Jun Wang
Affiliations: | Pharmaceutical Sciences | State University of New York, Buffalo, Buffalo, NY, United States |
Google:
"Jun Wang"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang J, Chen T, Ruszaj DM, et al. (2023) Integrated PK/PD modeling relates Smoothened inhibitor biomarkers to the heterogeneous intratumor disposition of cetuximab in pancreatic cancer tumor models. Journal of Pharmaceutical Sciences |
| Greene MK, Chen T, Robinson E, et al. (2020) Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer |
| Wang J, Chan DK, Sen A, et al. (2019) Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. Molecular Cancer Therapeutics |
| Chan D, Minx C, Wang J, et al. (2018) Abstract 3704: Efficacy of DR5-targeted immunoliposomes in pancreatic cancer models primed with SMO inhibitors Cancer Research. 78: 3704-3704 |
| Wang J, Qu Y, Pitoniak R, et al. (2014) Abstract 2691: Smo-targeted sonic hedgehog signaling inhibitor enhances therapeutic antibody deposition and efficacy in a patient-derived pancreatic ductal adenocarcinoma model Cancer Research. 74: 2691-2691 |